Citi raised the firm’s price target on Ideaya Biosciences (IDYA) to $65 from $64 and keeps a Buy rating on the shares. The firm is positive on the shares into the OptimUM-02 readout at the end of March.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target raised to $52 from $49 at Wedbush
- IDEAYA Biosciences: Buy Rating on Darovasertib/Crizotinib Ahead of Pivotal OpतimUM-02 Readout and Supported by Strong Cash Runway
- Ideaya Biosciences reports Q4 EPS (94c), consensus (95c)
- Ideaya Biosciences price target raised to $45 from $41 at RBC Capital
- Multiple Shots on Goal in High-Unmet-Need Oncology: IDEAYA’s Diversified Pipeline and Strong Funding Underpin Buy Rating